RAC

1.20%

$1.68 race oncology ltd

Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-58

First 58 Last

Share
Profile

Follow
Mason14

1,127 Posts.

12004

01/08/24

15:49

Post #: 75029750
Share

Originally posted by EDTD: ↑

I can only assume ASX11's point is that the other stock may be 'delisted' before that 12 month window for RAC is up. Hopefully, as I am a small holder from the 2 bucks days.

The only difficulty is, if you believe the other stock's prospects, it might be 2-3 times what it is now before delisting. (Maybe 4? I'm starting to get confused how 'platformy' the other stock is with this Alpha stuff in the works).

RAC's upside is more murky. I agree with others that $450 is pipe dream territory... but even the $30 chestnut everyone reckons is too low is 14 times from here. However whether that amount of upside is competing on the same 12 month timeline, I'm less sure.

I guess there is an argument that CPACS data ought to start rolling in assuming ethics/enrolment goes off without a hitch in the the next 6 months or so and we should in theory start getting healthy interest looking at how other stocks respond to such events. But the other stock has overcome inertia, we still need to get the snowball rolling from a somewhat standing start (ok, not completely, Dr T cornerstoned at 10c or whatever but we're still smallish market cap wise.)

As an aside I intensely get the sh*ts with some of the foam at the mouth "sell it all and buy RAC" posts that pop up from time to time. Find it grossly irresponsible. Even if you've got high hopes for RAC as many of us do, I find that sort of rabid up-ramping perversely switches on a bright orange caution light in my head despite my reading of announcements, Dr T's comms, research and the measured thoughts of other posters here. I am glad I'm not a new investor as while I likely would have still bought it would give me pause and I think it does this forum, and particularly beginner investors no favours.

Expand

Good post, my man.

What I would say is that the clinical history for Bisantrene easily warrants a $2B AUD MC.

You do not have to look far to see peers were sold for significantly more with considerably less.

I think you would struggle to find another opportunity as large, derisked, and undervalued on the ASX.

RAC Price at posting: $1.57 Sentiment: Buy Disclosure: Held
38 Upvote

0 Great analysis

Reply

Top Stories

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

There are more pages in this discussion • 24 more messages in this thread...

First 58 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.68		Change 0.020(1.20%)		Mkt cap ! $286.2M

Open	High	Low	Value	Volume
$1.68	$1.68	$1.61	$177.8K	108.9K

Buyers (Bids)

No.	Vol.	Price($)
1	1100	$1.64

Sellers (Offers)

Price($)	Vol.	No.
$1.68	4999	1

View Market Depth

No.	Vol.	Price($)
1	31221	1.625
1	5000	1.620
1	30000	1.615
2	16249	1.610
4	26875	1.600

Price($)	Vol.	No.
1.680	4999	1
1.720	17729	2
1.730	25792	1
1.750	508	1
1.780	4483	1

Last trade - 16.10pm 06/09/2024 (20 minute delay)

RAC (ASX) Chart

Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-58

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-58

Top Stories

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News